AVX 701

Drug Profile

AVX 701

Alternative Names: AVX701; Cancer vaccine VRP-CEA - AlphaVax; Carcinoembryonic antigen [CEA(6D)]-expressing virus-like replicon particle (VRP) immunotherapy - AlphaVax; CEA(6D) VRP vaccine - AlphaVax; VRP-CEA vaccine - AlphaVax; VRP-CEA(6D)

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator AlphaVax
  • Developer AlphaVax; Duke University Medical Center
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Colorectal cancer

Most Recent Events

  • 22 Sep 2015 Phase-I development for Colorectal cancer (Late-stage disease, Second-line therapy or greater) is ongoing in USA (NCT01890213)
  • 30 Nov 2013 Duke University initiates enrolment in a phase I trial for Colorectal cancer (late-stage disease) in the USA (NCT01890213)
  • 16 Jul 2013 Duke University plans a phase I trial for Colorectal cancer (late-stage disease) in USA (NCT01890213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top